TAD方案加美法仑治疗多发性骨髓瘤18例

目的观察TAD方案（亚砷酸、维生素C、地塞米松）联合美法仑治疗多发性骨髓瘤（MM）的临床疗效。方法18例MM患者，男12例，女6例。采用TAD方案加美法仑（亚砷酸10mg，第1天至第5天，第8天至第12天；维生素C1．0g，第1天至第5天，第8天至第12天；地塞米松20mg，第1天至第4天，第8天至第11天；美法仑2mg，3次／d，第1天至第12天）治疗初治及难治复发性MM，观察18例患者中完全缓解（CR）、部分反应（PR）、微小反应（MR）、无改变（NC）比例。结果18例患者中CR3例（16．7％），PR14例（77．7％），MR1例（5．6％）。结论亚砷酸、美法仑、维生素C、地塞米松联合应用是一种有效且副作用小的治疗初治或难治性MM的方案。

TAD regimen with melphalan to treat 18 cases of multiple myeloma

Objective To observe the clinical results of combination therapy for multiple myeloma by arsenic trioxide,melphalan,vitamin C and dexamethasone.Methods 18 cases with multiple myeloma,12 males and 6 females were given the treatment including arsenic trioxide,melphalan,vitamin C and dexamethasone combination therapy;the dosage of arsenic trioxide 10 mg,d1～5,d8～12;vitamin C 1.0 g,d1～5,d8～12;dexamethasone 20 mg,d1～4,d8～11;melphalan 2 mg,tid,d1～12.Complete response(CR),partial response(PR),minimal response(MR),no ehange(NC)were observed.Results The CR werel6.7%(3/18),PR were 77.7%(14/t8),MR were 5.6%(1/18).Conclusion Combinational arsenic trioxide,melphalan,vitamin C and dexamethasone is an effective therapy with less side effects,which can be considered for treating the initial or relapsed or refractory MM.